CERTIFIED SPECIALTY PHARMACIST
(CSP) EXAM – 2026-2027 ULTIMATE
PRACTICE TEST & STUDY GUIDE
PART 1: CSP EXAM DOMAINS SUMMARY
Domain I: Clinical Management of Specialty Diseases & Therapies
● Covers major therapeutic areas: oncology (e.g., checkpoint inhibitors, CAR-T),
immunology (e.g., TNF-alpha inhibitors, JAK inhibitors), infectious diseases (HCV
with DAAs, HIV with INSTIs), neurology (e.g., MS DMTs like ocrelizumab,
natalizumab), gastroenterology (e.g., vedolizumab, ustekinumab for IBD), and
ophthalmology (e.g., anti-VEGF agents like aflibercept).
● Focus on mechanism of action (MoA), black box warnings, baseline and ongoing
monitoring (e.g., LFTs for hepatotoxic drugs, CBC for myelosuppressive agents), and
management of immune-related adverse events (irAEs) per guidelines (e.g., NCCN,
ASCO, ACR).
● Key concepts: therapeutic drug monitoring (TDM) for select agents, vaccination
requirements (e.g., TB screening before anti-TNF therapy), and drug interactions
(e.g., CYP450 with small molecules).
Domain II: Patient Access, Services, and Adherence
● Navigates complex insurance barriers: benefits investigation (medical vs. pharmacy
benefit), prior authorization (PA) submissions, and denial appeals.
● Utilizes financial assistance: manufacturer co-pay cards (e.g., for commercially
insured), Patient Assistance Programs (PAPs) for uninsured, and foundation support
(e.g., PAN Foundation, HealthWell).
● Implements adherence strategies: medication synchronization, adherence packaging
(blister packs), refill reminders, and motivational interviewing techniques. Delivers
services via white-glove (nurse-led) or direct-to-patient models.
Domain III: Operations, Supply Chain, and Logistics
● Manages cold chain: storage (2–8°C or -20°C), validated shipping containers with
real-time temperature monitoring, and contingency planning for delays.
● Handles hazardous drugs per USP <800>: PPE (gloves, gowns), containment
primary engineering controls (C-PECs), spill kits, and proper disposal.
● Maintains inventory of high-cost, low-volume drugs with short shelf lives; executes
recalls swiftly. Complies with URAC or ACHC specialty pharmacy accreditation
standards for operational excellence.
,Domain IV: Legal, Regulatory, and Compliance
● Manages FDA REMS programs: enrolls prescribers/patients, verifies lab monitoring
(e.g., iPLEDGE for isotretinoin, STEPS for lenalidomide), and ensures safe use
conditions.
● Protects PHI per HIPAA Privacy/Security Rules: minimum necessary standard, BAAs,
encryption, and breach notification.
● Ensures 340B compliance: prohibits diversion, maintains auditable records, and
verifies patient eligibility. Avoids violations of Anti-Kickback Statute (AKS) and Stark
Law through transparent patient support programs and fair market value
arrangements.
● Adheres to state pharmacy board licensure and sterile compounding regulations
(USP <797> if applicable).
Domain V: Quality, Safety, and Outcomes
● Tracks key performance indicators: PDC (Proportion of Days Covered) for
adherence, time-to-fill (goal: <24–72 hours), first-fill abandonment rate, and patient
satisfaction (e.g., CG-CAHPS).
● Conducts quality improvement (QI) using PDSA cycles to address gaps (e.g.,
reducing PA denial rates).
● Reports serious adverse events to FDA MedWatch within 15 days; uses data
analytics to demonstrate clinical and economic value to payers (e.g., reduced
hospitalizations).
Domain VI: Business and Finance
● Distinguishes distribution models: "buy-and-bill" (provider purchases drug, bills
medical benefit) vs. specialty pharmacy (pharmacy dispenses, bills pharmacy
benefit).
● Understands reimbursement: J-codes for medical benefit, NDC-based billing for
pharmacy benefit, and spread pricing challenges.
● Manages gross-to-net: accounts for rebates, discounts, and chargebacks. Applies
basic economics: high cost, low volume, high service intensity define specialty drugs.
Domain VII: Professional Practice and Advocacy
● Collaborates in multidisciplinary teams: communicates with prescribers, nurses, and
social workers to optimize therapy.
● Applies ethical principles: autonomy (informed consent), justice (equitable access),
and non-maleficence (safety monitoring).
● Promotes health equity: addresses social determinants of health (SDOH), provides
culturally competent counseling, and advocates for policy changes (e.g., copay
accumulator adjustments).
PART 2: COMPREHENSIVE CSP PRACTICE EXAM
,1. A patient with rheumatoid arthritis is initiating tofacitinib. Which baseline laboratory test is
MOST critical before starting therapy?
A) Hemoglobin A1c
B) Lipid panel
C) Complete blood count (CBC) and liver function tests (LFTs)
D) Thyroid-stimulating hormone (TSH)
Answer: C
Tofacitinib (a JAK inhibitor) carries black box warnings for serious infections, malignancy,
and thrombosis. Baseline CBC and LFTs are required per FDA labeling and ACR guidelines
(Domain I). Options A, B, and D are not primary monitoring parameters for this agent.
2. A patient’s insurance denies coverage for ocrelizumab for multiple sclerosis, citing "not
medically necessary." What is the pharmacist’s BEST next step?
A) Switch the patient to a lower-cost generic alternative
B) Submit a peer-to-peer review request with the prescriber
C) Enroll the patient in a manufacturer co-pay assistance program
D) Discontinue the prescription and notify the prescriber
Answer: B
Peer-to-peer review allows the prescriber to discuss clinical rationale directly with the payer’s
medical director, often overturning inappropriate denials (Domain II). Switching without
prescriber input (A) is unsafe; co-pay assistance (C) doesn’t address coverage denial;
discontinuation (D) abandons care.
3. A specialty pharmacy receives a shipment of a monoclonal antibody that requires storage
at 2–8°C. The temperature logger shows a 4-hour excursion to 12°C during transit. What
should the pharmacy do?
A) Immediately dispense the product to avoid waste
B) Quarantine the product and contact the manufacturer for stability data
, C) Store it in the refrigerator and use it within 24 hours
D) Return it to the shipper without documentation
Answer: B
Temperature excursions require quarantine and manufacturer consultation per USP <1079>
and cold chain best practices (Domain III). Dispensing (A) or using without validation (C)
risks efficacy/safety; undocumented returns (D) violate traceability requirements.
4. A pharmacy enrolls a patient in a REMS program for lenalidomide. Which action is
REQUIRED under the REMS?
A) Verify the patient has received influenza and pneumococcal vaccines
B) Confirm negative pregnancy tests monthly for females of reproductive potential
C) Check renal function every 3 months
D) Ensure the patient has a private room for infusion
Answer: B
Lenalidomide REMS (RevAssist) mandates monthly pregnancy testing and two negative
tests before initiation for females of reproductive potential due to severe teratogenicity
(Domain IV). Vaccines (A) and renal checks (C) are general care; infusion (D) is not
applicable (oral drug).
5. Which metric is the gold standard for measuring medication adherence in specialty
pharmacy?
A) Medication Possession Ratio (MPR)
B) Proportion of Days Covered (PDC)
C) Pill count at refill
D) Patient self-report
Answer: B
(CSP) EXAM – 2026-2027 ULTIMATE
PRACTICE TEST & STUDY GUIDE
PART 1: CSP EXAM DOMAINS SUMMARY
Domain I: Clinical Management of Specialty Diseases & Therapies
● Covers major therapeutic areas: oncology (e.g., checkpoint inhibitors, CAR-T),
immunology (e.g., TNF-alpha inhibitors, JAK inhibitors), infectious diseases (HCV
with DAAs, HIV with INSTIs), neurology (e.g., MS DMTs like ocrelizumab,
natalizumab), gastroenterology (e.g., vedolizumab, ustekinumab for IBD), and
ophthalmology (e.g., anti-VEGF agents like aflibercept).
● Focus on mechanism of action (MoA), black box warnings, baseline and ongoing
monitoring (e.g., LFTs for hepatotoxic drugs, CBC for myelosuppressive agents), and
management of immune-related adverse events (irAEs) per guidelines (e.g., NCCN,
ASCO, ACR).
● Key concepts: therapeutic drug monitoring (TDM) for select agents, vaccination
requirements (e.g., TB screening before anti-TNF therapy), and drug interactions
(e.g., CYP450 with small molecules).
Domain II: Patient Access, Services, and Adherence
● Navigates complex insurance barriers: benefits investigation (medical vs. pharmacy
benefit), prior authorization (PA) submissions, and denial appeals.
● Utilizes financial assistance: manufacturer co-pay cards (e.g., for commercially
insured), Patient Assistance Programs (PAPs) for uninsured, and foundation support
(e.g., PAN Foundation, HealthWell).
● Implements adherence strategies: medication synchronization, adherence packaging
(blister packs), refill reminders, and motivational interviewing techniques. Delivers
services via white-glove (nurse-led) or direct-to-patient models.
Domain III: Operations, Supply Chain, and Logistics
● Manages cold chain: storage (2–8°C or -20°C), validated shipping containers with
real-time temperature monitoring, and contingency planning for delays.
● Handles hazardous drugs per USP <800>: PPE (gloves, gowns), containment
primary engineering controls (C-PECs), spill kits, and proper disposal.
● Maintains inventory of high-cost, low-volume drugs with short shelf lives; executes
recalls swiftly. Complies with URAC or ACHC specialty pharmacy accreditation
standards for operational excellence.
,Domain IV: Legal, Regulatory, and Compliance
● Manages FDA REMS programs: enrolls prescribers/patients, verifies lab monitoring
(e.g., iPLEDGE for isotretinoin, STEPS for lenalidomide), and ensures safe use
conditions.
● Protects PHI per HIPAA Privacy/Security Rules: minimum necessary standard, BAAs,
encryption, and breach notification.
● Ensures 340B compliance: prohibits diversion, maintains auditable records, and
verifies patient eligibility. Avoids violations of Anti-Kickback Statute (AKS) and Stark
Law through transparent patient support programs and fair market value
arrangements.
● Adheres to state pharmacy board licensure and sterile compounding regulations
(USP <797> if applicable).
Domain V: Quality, Safety, and Outcomes
● Tracks key performance indicators: PDC (Proportion of Days Covered) for
adherence, time-to-fill (goal: <24–72 hours), first-fill abandonment rate, and patient
satisfaction (e.g., CG-CAHPS).
● Conducts quality improvement (QI) using PDSA cycles to address gaps (e.g.,
reducing PA denial rates).
● Reports serious adverse events to FDA MedWatch within 15 days; uses data
analytics to demonstrate clinical and economic value to payers (e.g., reduced
hospitalizations).
Domain VI: Business and Finance
● Distinguishes distribution models: "buy-and-bill" (provider purchases drug, bills
medical benefit) vs. specialty pharmacy (pharmacy dispenses, bills pharmacy
benefit).
● Understands reimbursement: J-codes for medical benefit, NDC-based billing for
pharmacy benefit, and spread pricing challenges.
● Manages gross-to-net: accounts for rebates, discounts, and chargebacks. Applies
basic economics: high cost, low volume, high service intensity define specialty drugs.
Domain VII: Professional Practice and Advocacy
● Collaborates in multidisciplinary teams: communicates with prescribers, nurses, and
social workers to optimize therapy.
● Applies ethical principles: autonomy (informed consent), justice (equitable access),
and non-maleficence (safety monitoring).
● Promotes health equity: addresses social determinants of health (SDOH), provides
culturally competent counseling, and advocates for policy changes (e.g., copay
accumulator adjustments).
PART 2: COMPREHENSIVE CSP PRACTICE EXAM
,1. A patient with rheumatoid arthritis is initiating tofacitinib. Which baseline laboratory test is
MOST critical before starting therapy?
A) Hemoglobin A1c
B) Lipid panel
C) Complete blood count (CBC) and liver function tests (LFTs)
D) Thyroid-stimulating hormone (TSH)
Answer: C
Tofacitinib (a JAK inhibitor) carries black box warnings for serious infections, malignancy,
and thrombosis. Baseline CBC and LFTs are required per FDA labeling and ACR guidelines
(Domain I). Options A, B, and D are not primary monitoring parameters for this agent.
2. A patient’s insurance denies coverage for ocrelizumab for multiple sclerosis, citing "not
medically necessary." What is the pharmacist’s BEST next step?
A) Switch the patient to a lower-cost generic alternative
B) Submit a peer-to-peer review request with the prescriber
C) Enroll the patient in a manufacturer co-pay assistance program
D) Discontinue the prescription and notify the prescriber
Answer: B
Peer-to-peer review allows the prescriber to discuss clinical rationale directly with the payer’s
medical director, often overturning inappropriate denials (Domain II). Switching without
prescriber input (A) is unsafe; co-pay assistance (C) doesn’t address coverage denial;
discontinuation (D) abandons care.
3. A specialty pharmacy receives a shipment of a monoclonal antibody that requires storage
at 2–8°C. The temperature logger shows a 4-hour excursion to 12°C during transit. What
should the pharmacy do?
A) Immediately dispense the product to avoid waste
B) Quarantine the product and contact the manufacturer for stability data
, C) Store it in the refrigerator and use it within 24 hours
D) Return it to the shipper without documentation
Answer: B
Temperature excursions require quarantine and manufacturer consultation per USP <1079>
and cold chain best practices (Domain III). Dispensing (A) or using without validation (C)
risks efficacy/safety; undocumented returns (D) violate traceability requirements.
4. A pharmacy enrolls a patient in a REMS program for lenalidomide. Which action is
REQUIRED under the REMS?
A) Verify the patient has received influenza and pneumococcal vaccines
B) Confirm negative pregnancy tests monthly for females of reproductive potential
C) Check renal function every 3 months
D) Ensure the patient has a private room for infusion
Answer: B
Lenalidomide REMS (RevAssist) mandates monthly pregnancy testing and two negative
tests before initiation for females of reproductive potential due to severe teratogenicity
(Domain IV). Vaccines (A) and renal checks (C) are general care; infusion (D) is not
applicable (oral drug).
5. Which metric is the gold standard for measuring medication adherence in specialty
pharmacy?
A) Medication Possession Ratio (MPR)
B) Proportion of Days Covered (PDC)
C) Pill count at refill
D) Patient self-report
Answer: B
